| Primary information |
|---|
| SALID | SAL_12571 |
| Biomarker name | Pro-epidermal growth factor (EGF) [Cleaved into: Epidermal growth factor (Urogastrone)] |
| Biomarker Type | NA |
| Sampling Method | Age 50, Their age, sex, type of diabetes, method of control, average glucose level and history of smoking were obtained from reviews of their medical records and personal interviews. Twenty-one healthy individuals, free of medications and oral or systemic illness. |
| Collection Method | Patients were instructed to expectorate every 6 h into pre-labeled sterile collection tubes. Unstimulated whole resting saliva (approximately 3 ml) was obtained from each patient by passive expectoration |
| Analysis Method | Quantikine Human EGF Immunoassay |
| Collection Site | Whole Saliva |
| Disease Category | Metabolic Disorder |
| Disease/Condition | Diabetes Mellitus, Type 2 |
| Disease Subtype | NA |
| Fold Change/ Concentration | 1.20933977 |
| Up/Downregulated | Upregulated |
| Exosomal | NA |
| Organism | Homo sapiens |
| PMID | 10989322 |
| Year of Publication | 2000 |
| Biomarker ID | P01133 |
| Biomarker Category | Protein |
| Sequence | MLLTLIILLPVVSKFSFVSLSAPQHWSCPEGTLAGNGNSTCVGPAPFLIFSHGNSIFRIDTEGTNYEQLVVDAGVSVIMDFHYNEKRIYWVDLERQLLQRVFLNGSRQERVCNIEKNVSGMAINWINEEVIWSNQQEGIITVTDMKGNNSHILLSALKYPANVAVDPVERFIFWSSEVAGSLYRADLDGVGVKALLETSEKITAVSLDVLDKRLFWIQYNREGSNSLICSCDYDGGSVHISKHPTQHNLFAMSLFGDRIFYSTWKMKTIWIANKHTGKDMVRINLHSSFVPLGELKVVHPLAQPKAEDDTWEPEQKLCKLRKGNCSSTVCGQDLQSHLCMCAEGYALSRDRKYCEDVNECAFWNHGCTLGCKNTPGSYYCTCPVGFVLLPDGKRCHQLVSCPRNVSECSHDCVLTSEGPLCFCPEGSVLERDGKTCSGCSSPDNGGCSQLCVPLSPVSWECDCFPGYDLQLDEKSCAASGPQPFLLFANSQDIRHMHFDGTDYGTLLSQQMGMVYALDHDPVENKIYFAHTALKWIERANMDGSQRERLIEEGVDVPEGLAVDWIGRRFYWTDRGKSLIGRSDLNGKRSKIITKENISQPRGIAVHPMAKRLFWTDTGINPRIESSSLQGLGRLVIASSDLIWPSGITIDFLTDKLYWCDAKQSVIEMANLDGSKRRRLTQNDVGHPFAVAVFEDYVWFSDWAMPSVMRVNKRTGKDRVRLQGSMLKPSSLVVVHPLAKPGADPCLYQNGGCEHICKKRLGTAWCSCREGFMKASDGKTCLALDGHQLLAGGEVDLKNQVTPLDILSKTRVSEDNITESQHMLVAEIMVSDQDDCAPVGCSMYARCISEGEDATCQCLKGFAGDGKLCSDIDECEMGVPVCPPASSKCINTEGGYVCRCSEGYQGDGIHCLDIDECQLGEHSCGENASCTNTEGGYTCMCAGRLSEPGLICPDSTPPPHLREDDHHYSVRNSDSECPLSHDGYCLHDGVCMYIEALDKYACNCVVGYIGERCQYRDLKWWELRHAGHGQQQKVIVVAVCVVVLVMLLLLSLWGAHYYRTQKLLSKNPKNPYEESSRDVRSRRPADTEDGMSSCPQPWFVVIKEHQDLKNGGQPVAGEDGQAADGSMQPTSWRQEPQLCGMGTEQGCWIPVSSDKGSCPQVMERSFHMPSYGTQTLEGGVEKPHSLLSANPLWQQRALDPPHQMELTQ |
| Title of study | Salivary EGF levels reduced in diabetic patients |
| Abstract of study | Oral problems such as periodontitis are recognized major complications associated with diabetes. Salivary derived growth factors, including epidermal growth factor (EGF), are thought to play a role in helping maintain levels of oral health, promoting wound healing, and maintaining mucosal integrity. In the present study, salivary levels of EGF in diabetic vs. healthy control patients was evaluated. Twenty-one diabetic patients participated in this study. Age, race, sex and smoking histories were matched with 21 systematically healthy nondiabetic patients. Three milliliters of unstimulated resting whole saliva was collected from each patient at 6 h intervals up to 42 h and whole saliva protein concentrations were determined for each sample. EGF concentrations for each sample were quantitated spectrophometrically utilizing an immunoassay. Diabetic patients had greater salivary protein concentrations over 42 h of collection with a mean of 1.502+/-0.09 vs. 1.242+/-0.05 mg/ml for healthy control patients. The EGF concentration was significantly lower (p<0.05) for the diabetic patients compared to control patients, whether expressed relative to 1 ml volume of saliva (873.43+/-106.5 vs. 1101.09+/-116.8 pg/ml) or 1 mg whole saliva protein (629.18+/-92.6 vs. 931.20+/-124.6 pg/mg saliva protein). This study suggests that reduced levels of salivary EGF in diabetic patients may contribute to the development of oral and systemic complications of diabetes, which may have future clinical applications. |